[
  {
    "ts": "2025-10-01T15:40:04+00:00",
    "headline": "HOLX vs. IDXX: Which Stock Is the Better Value Option?",
    "summary": "HOLX vs. IDXX: Which Stock Is the Better Value Option?",
    "url": "https://finance.yahoo.com/news/holx-vs-idxx-stock-better-154004525.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "fbacdc87-f82a-339d-8801-b597704fb542",
      "content": {
        "id": "fbacdc87-f82a-339d-8801-b597704fb542",
        "contentType": "STORY",
        "title": "HOLX vs. IDXX: Which Stock Is the Better Value Option?",
        "description": "",
        "summary": "HOLX vs. IDXX: Which Stock Is the Better Value Option?",
        "pubDate": "2025-10-01T15:40:04Z",
        "displayTime": "2025-10-01T15:40:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y.YEouD16bNWn6FshAyysg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sqqoypFHTaqTKxA9xCsU7A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/holx-vs-idxx-stock-better-154004525.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/holx-vs-idxx-stock-better-154004525.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "IDXX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T13:10:00+00:00",
    "headline": "Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum",
    "summary": "HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.",
    "url": "https://finance.yahoo.com/news/hologic-bets-endomagnetics-fuel-interventional-131000801.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "b3c255a2-232b-3056-946a-98c5f3455efe",
      "content": {
        "id": "b3c255a2-232b-3056-946a-98c5f3455efe",
        "contentType": "STORY",
        "title": "Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum",
        "description": "",
        "summary": "HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.",
        "pubDate": "2025-10-01T13:10:00Z",
        "displayTime": "2025-10-01T13:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hologic-bets-endomagnetics-fuel-interventional-131000801.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hologic-bets-endomagnetics-fuel-interventional-131000801.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            },
            {
              "symbol": "SYK"
            },
            {
              "symbol": "HOLX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T11:30:00+00:00",
    "headline": "VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with Hologic Diagenode.",
    "summary": "By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT SIGNIFICANT RECENT NEWS VolitionRx’s (NYSE:VNRX) announcements of two significant licensing agreements in September 2025 represent the materialization of a key priority that was described during the second quarter 2025 conference call in August. During the call, CEO Cameron Reynolds relayed that the company was in confidential",
    "url": "https://finance.yahoo.com/news/vnrx-two-2-licensing-agreements-113000612.html",
    "source": "Zacks Small Cap Research",
    "provider": "yfinance",
    "raw": {
      "id": "86681b85-3d2b-36a6-97d9-9b966b173a3f",
      "content": {
        "id": "86681b85-3d2b-36a6-97d9-9b966b173a3f",
        "contentType": "STORY",
        "title": "VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with Hologic Diagenode.",
        "description": "",
        "summary": "By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT SIGNIFICANT RECENT NEWS VolitionRx’s (NYSE:VNRX) announcements of two significant licensing agreements in September 2025 represent the materialization of a key priority that was described during the second quarter 2025 conference call in August. During the call, CEO Cameron Reynolds relayed that the company was in confidential",
        "pubDate": "2025-10-01T11:30:00Z",
        "displayTime": "2025-10-01T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/scr.zacks.com/e036621dab3eb66ece1f69b9fcd5e04b",
          "originalWidth": 1138,
          "originalHeight": 590,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5X7oyhIF.OhVkOLsLv2niw--~B/aD01OTA7dz0xMTM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/e036621dab3eb66ece1f69b9fcd5e04b.cf.webp",
              "width": 1138,
              "height": 590,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Kb4gAG6pTlPjp6LJC_w7dQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/e036621dab3eb66ece1f69b9fcd5e04b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks Small Cap Research",
          "url": "http://scr.zacks.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vnrx-two-2-licensing-agreements-113000612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vnrx-two-2-licensing-agreements-113000612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "VNRX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]